8 May 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) has entered into a development agreement with US-based Strategic Drug Solutions, Inc. (SDS) to co-develop OROFLOW®, a novel intranasal spray designed to treat Oesophageal Motility Disorders (OMD). These are a group of conditions that impair the ability to swallow and significantly impact quality of life as a result.
The product is being developed using LTR Pharma’s proprietary nasal delivery platform, the same technology behind its lead products SPONTAN® and ROXUS®. OROFLOW® is designed to provide fast symptom relief for the impaired ability to swallow (potentially within 10 minutes). This represents a non-invasive alternative to current treatments for these conditions, which include surgery, botulinum toxin injections, and pneumatic dilation.
Highlights:
-
Collaboration with SDS will target an underserved and growing global market, valued at $4.5 billion in 2024 and forecast to reach $8.1 billion by 2034.
-
OROFLOW® aims to address dysphagia and other symptoms associated with OMD with a convenient, non-oral formulation.
-
The development program will begin with Proof-of-Concept testing in the coming months.
LTR Pharma Executive Chairman, Lee Rodne, stated: "OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges for patients. Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief.
The global prevalence of Oesophageal Motility Disorders has been increasing. We believe OROFLOW represents an important innovation that can significantly improve the quality of life for these patients. By addressing this specialised medical need with our proven nasal spray technology, we're pursuing a meaningful opportunity that aligns patient outcomes with long-term value creation."
Market Opportunity
The global market for treating OMD is currently valued at approximately $4.5 billion and is projected to grow to $8.1 billion by 2034, with a compound annual growth rate (CAGR) of 6.1%. The United States is the largest individual market at $1.94 billion, with significant potential also in East Asia (~$326 million).
Media Enquiries
Haley Chartres – [email protected]
Investor Enquiries
Peter McLennan – [email protected]
About us:
About LTR Pharma Limited (ASX:LTP)
LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas. LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
